Greg Verdine at Revolution Medicines and Tal Zaks at Moderna pushed biotech boundaries with risky, groundbreaking cancer experiments.
By
Hilary Brueck
You're currently following this author!
Want to unfollow? Unsubscribe via the link in your email.
Tal Zaks, the former chief medical officer of Moderna, said he took "a very large financial bet just based on first principle beliefs."
Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and…
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
Moderna still bullish on mRNA, Ipsen's acquisition of Kartos, and more biotech news from The Readout
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study…
Pharma Bro Martin Shkreli admits shorting Moderna at $80 just weeks before a landmark cancer vaccine win sparked a 177% stock…
